Last reviewed · How we verify
Pfizer PCV13
PCV13 is a pneumococcal conjugate vaccine that stimulates the immune system to produce antibodies against 13 serotypes of Streptococcus pneumoniae.
PCV13 is a pneumococcal conjugate vaccine that stimulates the immune system to produce antibodies against 13 serotypes of Streptococcus pneumoniae. Used for Prevention of invasive pneumococcal disease in infants and children, Prevention of pneumococcal pneumonia and otitis media in pediatric populations.
At a glance
| Generic name | Pfizer PCV13 |
|---|---|
| Sponsor | Walvax Biotechnology Co., Ltd. |
| Drug class | Pneumococcal conjugate vaccine |
| Target | Streptococcus pneumoniae polysaccharide capsule (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
The vaccine contains polysaccharide capsules from 13 different pneumococcal serotypes conjugated to a protein carrier, which enhances immunogenicity and T-cell dependent responses. This conjugation allows the vaccine to elicit both humoral and cellular immune responses, providing protection against invasive pneumococcal disease, pneumonia, and other pneumococcal infections caused by these serotypes.
Approved indications
- Prevention of invasive pneumococcal disease in infants and children
- Prevention of pneumococcal pneumonia and otitis media in pediatric populations
Common side effects
- Injection site erythema
- Injection site swelling
- Fever
- Irritability
- Drowsiness
Key clinical trials
- Vaccine Responses in Patients With B Cell Malignancies (PHASE4)
- Clinical Trial of PCV24 in Children Aged 2-17 Years (PHASE1)
- Safety and Immunogenicity Study of a 13-valent Pneumococcal Polysaccharide Conjugate Vaccine (PHASE1)
- The Effect of Fractional Doses of Pneumococcal Conjugate Vaccines on Immunogenicity and Carriage in Kenyan Infants (PHASE4)
- A Phase 3 Study to Evaluate the Immunogenicity and Safety of Walvax's PCV13-TT as Compared to Pfizer's PCV13 (PHASE3)
- Pneumococcal Vaccination of Multiple Myeloma Patients on Novel Agents (PHASE4)
- Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life (PHASE3)
- Induction of Immunity Against Streptococcus Pneumoniae in Adults With Inflammatory Bowel Disease (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |